E-Medicare Pharma
Online Medicine Pharmacy
0.00$
Tabrecta (Capmatinib) 200 mg is a medication used in the treatment of metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations. It belongs to a class of drugs known as kinase inhibitors, which work by blocking the activity of certain proteins involved in cancer cell growth and proliferation. Cabani 200 mg is particularly effective in targeting tumors with alterations in the MET gene, offering a promising therapeutic option for patients with this subtype of NSCLC.
1. Indications:
Cabani (Capmatinib) 200 mg is indicated for the treatment of metastatic NSCLC in adult patients with mutations in the MET exon 14 skipping (METex14) gene.
2. Pharmacology:
Cabani (Capmatinib) 200 mg exerts its pharmacological effects by selectively inhibiting the activity of the MET receptor tyrosine kinase. MET plays a crucial role in various cellular processes, including cell proliferation, survival, and migration. By blocking MET signaling, Cabani inhibits the growth and spread of cancer cells harboring MET exon 14 skipping mutations.
3. Dosage and Administration:
The recommended dosage of Cabani (Capmatinib) 200 mg may vary depending on individual patient characteristics and treatment response. Typically, the prescribed dose is 400 mg taken orally twice daily, with or without food. Patients should follow the dosing schedule provided by their healthcare provider and adhere to the prescribed regimen.
4. Interaction:
Cabani (Capmatinib) 200 mg may interact with other medications, including:
Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.
5. Side Effects:
Common side effects associated with Cabani (Capmatinib) 200 mg may include:
Patients should report any persistent or bothersome side effects to their healthcare provider for further evaluation and management.
6. Precautions and Warnings:
Before using Cabani (Capmatinib) 200 mg, patients should be aware of the following precautions:
7. Overdose Effects:
In case of overdose with Cabani (Capmatinib) 200 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Cabani overdose, and patients should seek immediate medical attention if overdose is suspected.
Generic Name: | Capmatinib |
---|---|
Theraputic Category: | Anti-Cancer |
Pack Size: | 56’s |
Previous Product
Next Product
Begin your journey to better health . Join now to unlock exclusive tips and insights sent straight to your inbox, empowering you to embrace a healthier lifestyle each and every day.
Online Medicine Pharmacy
+8801929123476 emedicarepharma@gmail.com
65, mymansingh High-way, Dhaka-1230, Bangladesh